As we recently summarized online here, Oregon has approved a temporary rule implementing SB 763, which requires licensure of pharmaceutical sales representatives who visit health care providers in the state of Oregon for 15 or more days in a calendar year. Pharmaceutical manufacturers with sales representatives who visit customers in Oregon for 15 or more days per year should take steps to make sure their sales representatives apply for and obtain licensure.
Oregon’s temporary rule took effect January 1, and the state’s Department of Consumer and Business Services (DCBS) is also debating a proposed permanent rule that will govern long-term implementation of SB 763, to take effect in June 2022. SB 763 is similar to laws currently in effect in Chicago, Washington D.C., and Nevada, and incorporates some of the more onerous requirements from those other jurisdictions, including that licensees are required to complete continuing education and submit annual reports describing their contact with health care providers in Oregon. Oregon has already started to accept licensure applications in accordance with SB 763 via the National Insurance Producer Registry.
See our full analysis online here for more information, including a summary of who must obtain a license, the requirements to obtain and maintain licensure, and penalties under SB 763.
We will continue to monitor the revision and finalization of the rules implementing Oregon SB 763, and keep you apprised of any changes.
Authored by Ron Wisor and Laura Hunter
Oregon adds licensure requirements for pharma sales reps
PhRMA responds: Code on Interactions with HCPs updated following fraud alert on speaker programs
No Surprises Act prohibits balance billing, creates arbitration process for out-of-network providers
COVID-19 Report for Life Sciences and Health Care Companies (Jan - Feb 2022)
Are you sure want to delete comment ?
Scan this QR Code to share this content
